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We assessed the ability of a kanamycin-marked Stx phage to move into a commensal, ovine Escherichia coli
strain in the ruminant gastrointestinal tract. Transduction was detected in 19/24 sheep tested, resulting in the
recovery of 47 transductants. Subtherapeutic doses of the quinolone antibiotic enrofloxacin did not increase the
rate of transduction.
Ruminants are thought to be the major reservoir of Shiga
toxin (Stx)-producing Escherichia coli (STEC), and most ani-
mals carry this organism in their gastrointestinal tract at some
point in their lifetime (2). Shiga toxins are encoded on lyso-
genic bacteriophages that can be transferred into a variety of
E. coli strains in vitro (11). While little is known about the
factors that influence phage transduction in vivo, bacterial
stress and induction of the SOS response could facilitate phage
movement, as has previously been observed in vitro (10). Quin-
olone antibiotics trigger the SOS response in E. coli, and sev-
eral studies have shown that these agents induce the transcrip-
tion of the stx2 genes in E. coli O157:H7 and increase the
production of Stx both in vitro and in vivo (7, 15, 16). Further-
more, subtherapeutic doses of ciprofloxacin have been shown
to increase the transduction of a marked Stx2 phage in the
gastrointestinal tract of mice (16). Enrofloxacin, a fluoroquin-
olone antibiotic that is metabolized to ciprofloxacin in host
tissues, is approved for the treatment of respiratory infections
in ruminants (9). The effects of low levels of quinolone anti-
biotics on Stx phage dynamics in the ruminant intestine have
not been explored.
The objective of this study was to determine if transduction
of a marked Stx phage could be documented in a ruminant
animal model and whether the administration of subtherapeu-
tic doses of enrofloxacin would substantially induce movement
of the phage.
E. coli strain C43 (recipient strain) was isolated from a
healthy sheep and did not contain any known virulence
genes (4). Strain 1:361, a clinical isolate of E. coli O157:H7,
was isolated from a nationwide surveillance study (D. W. K.
Acheson, K. Frankson, D. Willis, et al., Abstr. 98th Gen.
Meet. Am. Soc. Microbiol. 1998, abstr. C-205, 1998). Strain
1:361(stx2:kan), in which most of the stx2A gene is replaced
with the kanamycin resistance (Kanr) gene from Tn903, was
constructed using pCVD442/933-2-kan (13); this became the
donor strain. The donor and recipient strains were grown to
logarithmic phase and concentrated by centrifugation.
Following a 2-week period of acclimation to a commercial
diet of low-energy feed concentrate (3) and alfalfa/grass hay,
24 sheep were randomly assigned to three groups. Sheep were
orally inoculated with 5  1011 CFU of both the donor and
recipient E. coli strains. Group 1 did not receive antibiotics.
Enrofloxacin was administered subcutaneously to the sheep in
groups 2 (0.125 mg/kg/day, 5% of a therapeutic dose) and 3
(0.25 mg/kg/day, 10% of a therapeutic dose) on days 3 to 5
postinoculation (p.i.). Four additional sheep were given a ther-
apeutic dose of enrofloxacin (2.5 mg/kg). Fecal samples were
collected on days 1 to 6, 8, 10, 12, and 14 p.i. and cultured for
the inoculum strains and putative transductants as previously
described (3). Putative transductants were confirmed by PCR
using primers directed to the stx2A region containing the Kan
insertion. Sheep were necropsied at 2 weeks p.i.
Transduction of the Stx-encoding phage in sheep. The mean
magnitude of fecal shedding for both the donor and recipient
strains in each of the three groups of sheep is shown in Fig. 1.
During the time period when enrofloxacin was administered to
groups 2 and 3 (samples from days 4 to 6 p.i.), the donor strain
decreased 100-fold in the control group (Fig. 1A), 1,000-fold in
group 2 (Fig. 1B), and 10,000-fold in group 3 (Fig. 1C). By
day 6, the 10% enrofloxacin dose decreased the quantity of the
donor strain recovered by 1,000-fold compared to that recov-
ered from the sheep that did not receive the antibiotic. In
contrast, the recipient strain decreased approximately 10-fold
in all three groups of sheep during the same time period. The
donor E. coli O157:H7 strain was not recovered from three out
of four sheep given the therapeutic dose of enrofloxacin but
was recovered from one animal on day 12 (102 CFU/g) (data
not shown).
Overall, transductants were recovered from seven of eight
sheep in group 1, from four of eight sheep in group 2 and from
eight of eight sheep in group 3. The majority of transductants
(33/47) were recovered from all groups of sheep within the first
3 days (prior to the administration of enrofloxacin) (Table 1).
On days 4 to 15 p.i., transductants were recovered from four of
eight sheep in group 1 (five transductants), from four of eight
sheep in group 2 (six transductants), and from two of eight
sheep in group 3 (three transductants). In all cases, transduc-
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tants were recovered only at enrichment levels (50 CFU/g)
regardless of whether the animal had received enrofloxacin or
not. Transductants were not recovered from any of the tissues
or samples taken at necropsy or from the four sheep given the
therapeutic dose of enrofloxacin.
Our data clearly indicate that the transduction of the Stx-
encoding phage can occur in vivo in the ovine gastrointestinal
tract. Viable transductants were recovered from 19/24 animals
tested. If our results are representative of a variety of STEC
strains, it would suggest that the rate of transduction of the Stx
phage is between 107 and 105 in vivo. A variety of patho-
genic and commensal E. coli strains isolated from both humans
and animals are capable of lysogenizing detoxified Stx phages
(6, 11, 14). The experimental transduction of a marked Stx
phage from donor E. coli K-12 to recipient E. coli K-12 strains
has previously been demonstrated using an orally inoculated
mouse model (1). Our data extend these findings and demon-
strate that this movement also occurs in the ruminant gastro-
intestinal tract between a clinical E. coli O157:H7 isolate and a
commensal, ovine E. coli recipient. It also suggests that natu-
rally occurring transduction within the ruminant reservoir may
be one source for the expansion of STEC strains across differ-
ent serotypes of E. coli.
In vitro, low doses of ciprofloxacin induce both plaque
formation and Stx production in E. coli O157:H7 (16). Fur-
thermore, subtherapeutic doses of ciprofloxacin given to
streptomycin-treated mice increased the concentration of
intraintestinal Stx and mortality compared to control mice or
those given fosfomycin even though the viable number of E.
coli O157:H7 decreased by 1,000-fold. An increase in phage
transduction also occurred in mice treated with subtherapeutic
doses of ciprofloxacin that were inoculated with an E. coli K-12
strain harboring a Kan-marked Stx phage compared to the
transduction rate in control mice. The increase in phage move-
ment in mice is in contrast to what we observed in ruminants
treated with an equivalent antibiotic and dosage regimen. One
important point to bear in mind is that we did not have any
corroboration that the doses of enrofloxacin used caused
phage induction in vivo, and several factors may explain the
differing responses of Stx phages to quinolone antibiotics in the
mouse and sheep intestine. In our experiments, we used wild-
type E. coli strains for both the donor and recipient strains
rather than E. coli K-12. It is possible that E. coli K-12 strains
are more permissive to transduction in vivo than are wild-type
E. coli strains. Such differences have been demonstrated in
vitro (8). Pretreatment of the mouse intestine with streptomy-
cin, which removes much of the natural facultative intestinal
FIG. 1. Geometric mean of fecal shedding of donor E. coli
O157:H7 (1:361stx2:kan) (F) and recipient E. coli (C43) (E) strains
from (A) control sheep, (B) sheep given 0.125 mg/kg/day of enrofloxa-
cin, and (C) sheep given 0.25 mg/kg/day of enrofloxacin. Enrofloxacin
was given on days 3 to 5 p.i. (samples at days 4 to 6 p.i. are shown in
the bracketed areas). Bars indicate the standard errors.
TABLE 1. Recovery of transductants from sheep inoculated with
donor E. coli O157:H7 (1:361stx2:kan) and a recipient,
commensal E. coli (C43)
Antibiotic
dosea
No. of sheep from which transductants were




1 2 3 4 5 6 8 10 12 14
None 3/8 2/8 4/8 3/8 1/8 0/8 1/8 0/8 0/8 0/8 14
0.125 mg/kg 2/8 3/8 2/8 3/8 0/8 0/8 2/8 1/8 0/8 0/8 13
0.25 mg/kg 4/8 7/8 5/8 2/8 1/8 0/8 0/8 0/8 0/8 0/8 19
a Enrofloxacin was given on days 3, 4, and 5 p.i.
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flora, may facilitate donor-recipient cell interaction within the
intestine. In contrast, the established and competing micro-
flora in the sheep may effectively interfere with the colocaliza-
tion of the donor and recipient strains, resulting in a reduced
level of interaction. Also, bile salts have been shown to atten-
uate the excision of Stx phages in vitro (12) and to repress the
expression of cholera toxin and the toxin-coregulated pilus of
Vibrio cholerae (5).
A better understanding of phage movement in vivo could
provide clues as to why STEC strains are maintained in the
gastrointestinal tract of ruminants as well as the processes
behind the generation of new STEC strains.
(A preliminary report of this work was presented at the
105th General Meeting of the American Society for Microbi-
ology, Atlanta, Ga., 6 June 2005.)
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